Ryan Huntsman
Podiatrist · Salem, ORNPI 1609281534
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 128 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Smith+Nephew at 37.1% of the total. Reporting peaked in 2019 at $963 and has fallen 94.8% since, to $50 in 2025.
Across 128 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$998
- Integra Lifesciences Corporation$507
- Stryker$199
- Amgen$181
- Paratek Pharmaceuticals, Inc.$150
- Innovation Technologies Inc$135
- plus $522 from 19 others
What the payments were for
- Food & beverage$2,690100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 60 | $998 |
| Integra Lifesciences Corporation | 11 | $507 |
| Stryker(2 entities) | 4 | $199 |
| Amgen | 20 | $181 |
| Paratek Pharmaceuticals, Inc. | 9 | $150 |
| Innovation Technologies Inc | 2 | $135 |
| Medtronic | 1 | $116 |
| Bioventus LLC | 3 | $56 |
| Organogenesis Inc. | 1 | $50 |
| Zyla Life Sciences, Inc. | 2 | $37 |
| KCI USA, Inc. | 1 | $35 |
| GRT US Holding, Inc. | 1 | $26 |
| Triad Life Sciences Inc. | 1 | $24 |
| Misonix Inc | 1 | $21 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| Reapplix Inc. | 1 | $17 |
| Polarityte, Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Assertio Therapeutics, Inc. | 1 | $15 |
| Paragon 28, Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Aroa Biosurgery Incorporated | 1 | $12 |
| Osiris Therapeutics Inc. | 1 | $12 |
| Arteriocyte Medical Systems, Inc. | 1 | $12 |
| Zimmer Biomet | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,690 in reported general payments places this provider in the 65th percentile of 74 podiatrist providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Monohydrate | 105 | $1,144 |
| Mupirocin | 49 | $529 |
| Ammonium Lactate | 11 | $323 |
| Cefadroxil | 24 | $299 |
| Triamcinolone Acetonide | 20 | $278 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Salem
- John CallahanSalem$239
- Rick McClureMedford$133K
- Cyaandi DoveGrand Ronde$51K
- Stephen SchroederTigard$28K
- Colin MizuoHillsboro$18K
- Melinda NicholesPortland$15K
- Amanda KameryEugene$9K
- Peter PhamBeaverton$8K
- Liang-Chieh KoEugene$7K
- Kyle VillaruzGrants Pass$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.